

Prof. Dror Harats, MD

Prof. Harats is currently a professor of medicine in the department of biochemistry at the Sackler Faculty of Medicine, Tel-Aviv University, Israel. At The Sheba Medical Center, Tel-Hashomer, Israel he is serving as President of the Bert Strassburger Lipid Center, Acting Vice President of Research and Development and Academy and Chairman of the IRB committee. He is the CEO of Vascular Biogenics Ltd (VBL).

Prof. Harats is a graduate of the Hadassah Medical School at the Hebrew University, Jerusalem. He completed his residency in Internal Medicine at Hadassah and fellowship in Pulmonary and molecular biology at the University of California, San Francisco (UCSF).

For the past 25 years Prof. Harats has been involved in "cutting edge" Research in Lipid Metabolism, Atherosclerosis and Vascular Biology. He was one of the pioneers who discovered the role of the immune system in atherosclerosis and invented a new genetic tool for the treatment of angiogenesis, a process that plays a major role in cancer and cardiovascular disorders. Prof. Harats founded VBL in 2000. VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first in class treatments for cancer.

His research was published in more than 180 papers and chapters in books, and rewarded him with numerous prizes and grants in the field of atherosclerosis and cancer.